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Abstract
There are three theories of cancer development analyzed in this review. The first theory is the immunological theory, which states 
that cancer is a result of the immune system failing to detect a cancerous cell in which results in uncontrolled cell growth. The second 
theory is the somatic mutation theory, which states that genetic mutations are a direct cause cancer. The third theory is the stem 
cell theory which states that cancer results from an uncontrolled stem cell. The difference in each theory helps guide a clinician’s 
judgment in how to treat cancer. If a clinician believes in the immunological theory, he/she will view the best route of treatment as 
being by targeting the patient’s immune system. One who believes somatic mutation theory would say that the patient’s genetic 
makeup of the patient is the ideal target for treatment. One who believes in the stem cell theory would say that the only method of 
treatment is to remove the cancer entirely as any residual cancer will return. Based on all the evidence it appears that there is not 
one individual factor that causes cancer development, rather it is a combination of several factors that result in cancer.
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Introduction
In 2013 cancer was reported to affect over 1.6 million 
people (Siegel, et al., 2013). Despite cancer being such a 
highly discussed and researched disease there are many 
things that remain unknown. One of the major debates is 
how cancer develops; there are three major schools of 
thought: the immunological theory, the somatic mutation 
theory, and the stem cell theory.
The immunological theory postulates that cancer de-
velops as a result of the immune system failing to detect 
the cancerous cell. As a result of an undetected cell the 
cancer grows at an uncontrolled and dangerous rate, 
thereby damaging the host. If this is the sole etiology of 
cancer, the immune system could be harnessed to treat 
a person who had developed cancer. For example, a new 
cancer vaccine has been developed for prostate cancer 
patients. This vaccine was developed for two reasons. 
Firstly, prostate cancer cells have several tumor-associat-
ed antigens. Secondly, because the prostate is a nonessen-
tial organ, annihilation of any normal prostate tissue that 
comes about because of the immune response has no 
clinical consequence (Singh & Gulley, 2014). While not all 
cancers have these qualifications that make them suscep-
tible to a vaccine, other forms of immunotherapies are in 
development to try and take advantage of the specifics of 
each cancer to attack it immunologically.
The somatic mutation theory postulates cancer devel-
ops due to a genetic mutation leading to uncontrolled 
growth. A study showed that there are specific gene mu-
tations involved in breast and ovarian cancer. These are 
mutations of either the BRCA1 or BRCA2 gene (Miki, 
et al., 1994). More specifically, it has been shown that 
women with BRCA1 mutation by age 80 have a 72 per-
cent chance of developing breast cancer. While women 
who have the BRCA 2 mutation have a 69 percent chance 
of developing breast cancer (Kuchenbaecker, et al., 2017). 
Treatments based on this theory focuses more on the 
genetics of a person and using that field as a method to 
control or treat the cancer.
The stem cell theory of cancer assumes that cancer de-
velops because there is an uncontrolled stem cell in the 
body. All humans develop from stem cells that multiply 
repeatedly. However, during human development stem 
cells become specialized and eventually stop multiplying. 
This theory of cancer development says that cancer re-
sults from a stem cell that has not “turned off”, resulting 
in uncontrolled growth to the point of being detrimental 
to the host. This theory has many implications. Some cli-
nicians evaluate a cancer treatment based on how much 
it causes the tumor to shrink, but without removing the 
source the tumor will come back very quickly because 
the stem cells are still there. Physicians and Oncologists 
who subscribe to the stem cell theory may treat cancers 
differently than those who believe in the immunological 
theory or the somatic mutation theory.
The significance of each theory is that the information 
regarding how the disease develops can help determine 
the best course of treatment. Evidence seems to point to 
all three of these theories, hence there is no conclusive 
explanation. This review will examine all the evidence in 
order to determine which hypothesis best explains the 
development of cancer.
Methods
The articles and journals used in this review were found 
on PubMed, Ebsco, and Google Scholar. These articles 
were carefully reviewed in order to determine their rel-
evance to the thesis.
Discussion 
Immunological Theory of Cancer
This theory has been associated with three general steps 
the body constantly goes through: elimination, equilibrium 
and escape. The elimination step consists of the immune 
system surveying for all cancerous cells and destroying 
them. However, there are times when tumorous cells re-
main undetected while remaining dormant. This period is 
defined as equilibrium because there are cancerous cells 
in the body, but they are not doing any harm. The final 
step is escape in which the tumor gains dominance over 
the immune system and starts spreading (Lopez, et al., 
2016). This implies that the immune system’s activity and 
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ability to detect cancerous cells is important before the 
cancer gets out of hand.
To try to determine how immune activity affects cancer, 
residents of Japan, mostly above 40, were given a ques-
tionnaire that covered 90 lifestyle factors. People who 
participated in the study gave a peripheral blood sam-
ple after fasting for over 12 hours. A follow-up was per-
formed 11 years later where cancer incidence and death 
totals were gathered. Based on the questionnaire, each 
patient was assessed for cancer risk at one of three levels, 
low, medium, or high. Of the 8552 individuals who took 
the survey, 211 of the 3625 whose blood was sampled 
were identified as cancer cases. A number of the cases 
had to be excluded based on age, blood samples being 
inaccessible, etc. The total number of cases remaining was 
154, 92 men and 62 women. Accounting for age, it was 
found that patients with lower cytotoxicity activity, were 
at a significantly higher risk for developing cancer when 
compared to those with medium or high activity (Imai, 
et al., 2000). This study points to the fact that cytotoxic 
activity can help a person fight cancer, further illustrating 
that the immune system plays a role in cancer treatment.
A specific type of immunotherapy is currently being 
developed in which some of the patient’s T-cells are 
extracted and modified to become chimeric antigen re-
ceptor t-Cells (CAR-T cells). These T-cells are then given 
artificial receptors that are from monoclonal antibodies 
which allow the CAR-T cell to bind to the cancer cells. 
The patient is then treated with chemotherapy to elim-
inate any immunosuppressant activity in the body. The 
CAR-T cells are then injected and are free to attack the 
cancer cells. This treatment sounds perfect but there are 
some complications that arise. Cytokine release syn-
drome (CRS) is a life-threatening complication in which 
the immune system goes into a state of being overly ac-
tive and releases an excessive number of cytokines which 
results in organ toxicity. CRS is manageable but one has 
to be conscious of it when treating a patient with CAR-T. 
Another complication that can arise is CAR-T cell related 
encephalopathy syndrome. This syndrome can result in 
some patients feeling slightly disoriented while others can 
have seizures (Graham, et al., 2018). This methodology of 
cancer treatment is new but is showing great promise. It 
shows that the immune system, under careful monitoring, 
can be harnessed to fight cancers. 
A person’s immune system doesn’t allow cancer cells 
to grow because the natural killer cells, or NK cells de-
tect the cancers and kill them. These cells can identify a 
cancerous cell because they identify which cells are “not 
self” cells by searching for specific receptors that only 
one’s own cells have. Therefore, they find the cancer cell 
and kill it before it starts growing. Although some cancer 
cells go undetected, there are researchers who believe 
that the NK cells can be used to kill an active cancer. 
A new treatment is being studied in which NK cells are 
being combined with the concept of CAR-T cells cre-
ating CAR-NK cells. These cells have several advantages 
over CAR-T cells. Firstly, because NK cells have natural 
receptors for tumors, they have an easier time identi-
fying cancer cells even if the CAR portion of the cell is 
downregulated by the cancer. Secondly, CAR-NK cells do 
not undergo clonal expansion or immune rejection thus 
eliminating the issue of cytokine release syndrome that 
is present with CAR-T cells. Lastly, HLA matching is not 
necessary for CAR-NK cells, which means the graph-ver-
sus-host disease is not an issue when it comes to CAR-
NK cell treatment. Currently there is not enough clinical 
data to fully implement the treatment, however, there are 
studies being performed to help investigate new treat-
ment options. For example, CAR-NK cells are being re-
searched to help determine their ability to fight hemato-
logical and solid tumors, including glioblastoma, prostate 
cancer, and ovarian cancer (Hu, et al., 2019). While this 
treatment is in very early stages it has had great results 
thus far. If this treatment can prove to be effective it can 
have massive implications in the successful treatment of 
cancers because there are few side-effects. 
Dendritic cells are another one of the immune cells 
being used to fight cancer. Dendritic cells function as an 
antigen presenting cell meaning, when it recognizes an 
antigen it alerts the body to produce antibodies. There 
are vaccines that have been proven to work that are pre-
pared by removing a patient’s dendritic cells and “teach-
ing” them to recognize cancer cells, then reinjecting them 
into the patient. Once these dendritic cells are in the 
bloodstream, they can identify the cancer cells and initiate 
a T-Cell response to them. However, there were several 
issues when the dendritic cells were taken from ex vivo 
and put inside patients. Firstly, some patients experienced 
a T-cell response from the injection, but it did not result 
in significant improvement. This alteration in functional-
ity could be a result of the cells being transferred from 
an in vivo environment to an ex vivo environment, then 
returned to in vivo. Another issue with the vaccine is 
that the process is very time-consuming and expensive. 
Lastly, the dendritic cell vaccine is reliant on the patient’s 
immune system and its function. Because of this, in vivo 
preparation of the dendritic cell is still being perfected 
(Le Gall, et al., 2018). This technique can be very helpful to 
cancer patients as often the cancer proliferates because 
the immune system fails to recognize the cancer cells. 
With this treatment the incidents of cancer cells going 
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undetected can be virtually eliminated resulting in the 
body halting the cancer cells growth.
Another form of immunotherapy using dendritic cells 
is called dendritic-cell cytokine induced killer cells (DC-
CIK). In the study, there were several criteria that had to 
be met when determining who was an appropriate can-
didate. The first requirement was that the patients had to 
have advanced cancer (stages 3-5). Secondly, prior to this 
study, patients had to have received first-line treatment, 
including surgery, adjuvant chemotherapy and/or radio-
therapy. The study examined a total of 142 patients with 
histologically confirmed colorectal carcinoma, 71 were 
treated with DC-CIK and 71 were not. Patients were ex-
amined at three separate times, after 1, 3 and 5 years. The 
retrospective study found that patients who were treated 
with DC-CIK had 1,3 and 5-year prolonged progression 
free survival and overall survival versus those who were 
not treated. Minor side-effects were experienced by the 
patients treated with DC-CIK such as mild fever, chills, 
fatigue, while three also developed a headache and one 
developed chest tightness and hypotension. While these 
symptoms cannot be ignored, in the grand scheme of can-
cer treatment these side-effects are very mild. This study 
shows the effectiveness of DC-CIK and its ability to com-
bat colorectal cancer in patients who were treated with 
first-line treatments (Xie, et al., 2017). While this study 
has its limitations because it required first line treatment 
such as surgery, it does provide a powerful tool for pa-
tients who have already gone through or may require first 
line treatments.
The examples listed above all seem to point to the ac-
curacy of the immunological theory of cancer. Perhaps the 
most indicative proof that cancer prevention is a function 
of the immune system is from a study performed several 
years ago which analyzed 12 patients with glioblastoma 
who received regular course of immunotherapy (a den-
dritic cell vaccine). However, a few patients were also 
given a tetanus vaccine. The patients who were given the 
immunotherapy and the tetanus vaccine lived between 
four to eight years after their treatment. The patients who 
received the immunotherapy with another placebo drug 
lived only 11 months following their treatment (Mitchell, 
et al., 2015). The reason the tetanus shot impacts the can-
cer defense is because once given, the body begins to 
create t-cells as a typical reaction to a vaccine. Due to this 
additional t-cell production the body was more prepared 
to fight the cancer as well (Haelle, 2015). While this study 
was performed on a small sample size the results point to 
the same conclusion as the previous studies; it illustrates 
the role the immune system plays when fighting cancer.
These are just some of the treatments in development, 
all working under the assumption of the immunological 
theory of cancer being correct. As it stands, the treat-
ments appear promising and with further research they 
can hopefully be perfected and cancer patients can be 
cured with minimal side effects. All the studies cited point 
to the immunological theory of cancer as a very real and 
likely explanation for cancer development.
Somatic Mutation Theory of Cancer
The somatic mutation theory analyzes the development 
of cancer by looking at genetic factors. The specific ge-
netic variances in squamous cell carcinoma (SCC), adeno-
carcinoma (AC), and adenosquamous carcinoma (ASC), 3 
types of cervical cancers, were analyzed. Three hundred 
and one patients with SCC, AC, or ASC who were all 
treated with radical hysterectomy with lymphadenec-
tomy as their primary treatment were analyzed. All fol-
low-up data was obtained 5 years after primary treat-
ment. One hundred and sixty-six (55%) of the patients 
had SCC, fifty-five (18%) had AC and eighty (27%) had 
ASC. In 103 of the tumors there were 123 somatic muta-
tions detected as roughly 4% of the tumors had multiple 
mutations. The specific mutations were identified for each 
cancer. The PIK3CA was most common in SCC and ASC 
while KRAS was most common in AC. However, in each 
type of cervical cancer there was not only one mutation 
rather there were several mutations found across multi-
ple genes such as, PTEN, PPP2R1A, CTNNB1, CDKN2A, 
FBXW7, FGFR3, NRAS, and HRAS. The KRAS mutation 
is not exclusive to cervical cancers as it has also been 
linked to colorectal, lung and pancreatic cancers. KRAS 
and PIK3CA mutations were both not associated with 
survival; however a clear trend of lower survival rate was 
in patients carrying a PIK3CA mutation (Spaans, et al., 
2015). This study points to a connection between specific 
cancers and mutations that result in them. If an unknown 
cancer’s genetic sequence could be inspected it could give 
a clinician a clear idea of what cancer he/she is dealing 
with and how to properly treat that patient.
Cervical cancers are not the only cancers to have a 
gene associated with them as prostate cancers were also 
found to have specific genes connected to them. These 
genes were identified by looking at a prostate specific 
antigen (PSA) a protease produced in the prostate, as 
well as prostatic acid phosphatase (PAP). By looking at 
these two markers the researchers used the technique of 
guilt-by-association which works based on combinatoric 
measure of association. Forty-thousand different genes 
were analyzed, and each gene was determined to be 
present in prostate cancers if the cDNA corresponding 
to that gene is detected in the library. Upon analysis of all 
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40,000 genes most of them were determined to not be 
related to prostate cancer. However, eight of the genes 
were identified as being associated with it (Walker, et al., 
1999). The extent of their association is difficult to prove 
because correlation is more provable than causality, but 
the association is significant none the less.
Certain genes have been identified as being related to 
breast cancer that is metastatic to bone. One hundred 
and seven breast cancer patients who had developed 
metastasis had their negative-lymph nodes biopsied. 
Sixty-nine of the relapses were categorized as bone 
while 38 were labeled as not bone. Upon analysis, 69 sig-
nificantly unique gene sets were discovered across bone 
and non-bone samples. The five most common genes in 
bone cancer were TFF1, TFF3, AGR2, NAT1, and CRIP1. 
TFF1 was studied in 122 independent breast tumors in 
node-negative patients which indicates it is the most 
prevalent mutation. The researches then attempted to 
predict a correlation between a cancer’s gene sets and 
that cancer spreading to the bone. The samples were di-
vided into a test set and a training set. Five hundred and 
eighty-eight genes were selected and subjected to PAM 
analysis. A 31-gene predictor was selected after 10-fold 
cross validation that could identify relapse to the bone 
at 100% sensitivity and 50% specificity. The predictor 
showed 79.3% positive predictive value and TIFF1 was 
present in the gene list. Two random gene sets of 50 
and 100 genes were analyzed to test the validity of this 
method. Twenty-nine of the 50 random genes showed 
100% sensitivity and of these 29, the average specificity 
is 13.2% which indicates that the 50% specificity found 
by the earlier gene list is significantly higher than a ran-
dom gene set. Based on SAM sets the researchers de-
termined that the most common genes associated with 
the cancer metastases were TFF1 and TFF3. TFF3 was 
also found as overexpressed in some metastatic pros-
tate cancers, while TFF1 was found to induce cellular 
invasion of kidney and colon cancer (Smid, et al., 2006). 
This further proves that there is a strong tie between 
cancer and genetics. 
In high-grade serous ovarian cancers, triple-nega-
tive breast cancers, esophageal cancers, small-cell lung 
cancers, and squamous cell lung cancers, the p53 gene 
is mutated in at least 80% of patients’ tissue samples 
(Duffy, et al., 2017). P53 has two major functions in the 
cell cycle thereby linking it to cancer. P53 serves as a 
cell cycle regulator, so if the cell no longer needs to go 
through the cell cycle p53 will stop the cycle. Another 
function is that a normal p53 protein stops a cell that 
has already grown too much and is technically cancer-
ous by initiating apoptosis for that cell (Zilfou & Lowe, 
2009). When p53 is mutated the cells experience un-
controlled growth either because its cell cycle is not 
arrested or because a cell that is already out of control 
is not sent to apoptosis. 
Because of the prevalence of mutant p53 in cancer 
patient’s researchers have looked into a way to stabilize 
these mutant forms of p53. They analyzed mice whose 
p53 proteins were removed by one of several methods. 
One method was that the mice were injected with an 
anti-p53 antibody in which the p53 proteins in the mice 
underwent ubiquitination. Another method was by using 
an adenovirus, either Ad/GFP (green fluorescent pro-
tein) or Ad/His. They found that when these mice were 
exposed to a drug called CP-31398, not only was the 
DNA binding activity of mutant p53 restored thus al-
lowing cell cycle arrest and induction of apoptosis, but it 
can also increase the steady-state levels of wild type p53 
(Takimoto, et al., 2002). Another study showed that CP-
31398 also inhibited the ubiquitination of p53 proteins. 
A non-small-cell lung carcinoma cell, H460, was exposed 
to CP-31398 for an hour, it was then exposed to ALLN, 
a proteasome inhibitor, for four hours. Another group 
of cells was exposed to ALLN alone and both were 
analyzed. The results showed that the cells that had 
just been exposed to ALLN showed a typical pattern 
of ubiquitinated p53 ladders. However, the cells treated 
with a mixture of CP-31398 and ALLN or just CP-31398 
alone showed no ubiquitinated p53 ladders (Wang, et al., 
2003). These two applications of CP-31398 demonstrate 
how useful it can be in preventing cancer because of the 
prevalence of p53 mutations in cancer patients.
Another protein that has been a target for treatment 
is p21, a cell cycle inhibitor, cell proliferation effector, 
and apoptosis regulator. As with p53, many cancer 
patients have been shown to have their p21 proteins 
mutated. Gene editing techniques such as CRISPR, 
TALEN’s, ZFN’s and rAAV have all been used to change 
p21 expression and have been shown to suppress tu-
morigenesis phenotypes and reduce drug resistance. 
Several chemical treatments target p21 as well. Histone 
deacetylase inhibitors help increase the expression of 
p21. Trichostatin A, PAC-320, and HDAC inhibitor com-
bined with bortezomib or doxorubicin, have shown to 
enhance p21 expression in pancreatic cancer, prostate 
cancer and ovarian cancer respectively (Shamloo & 
Usluer, 2019). All these treatments targeting p21 can 
have massive ramifications because of p21’s effect on 
cell cycle arrest.
Specific genetic mutations are directly linked to spe-
cific cancers which seemingly indicates that certain 
genetic mutations are linked to specific cancers, thus 
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legitimizing the claim that cancers have genetic compo-
nents to them.
Stem Cell Theory of Cancer
This theory assumes that cancer is a result of a stem cell 
that is unregulated and grows uncontrollably. Because of 
several unique characteristics of prostate cancer such as 
histological heterogeneity, metastatic growth, drug resis-
tance, and distant relapse after effective primary treat-
ment, the stem cell theory was proposed as a possible 
explanation for prostate cancer. It was tested by search-
ing for stem cell markers in the cancerous tissue. While 
there is not one marker specific for prostate cancer stem 
cells, there are a few methods used to help identify the 
stem cells such as: β1 integrins, CD133, CD44, stem cell 
antigen 1 and the ABCG2-associated drug-resistance 
proteins. β1 is a marker for “stemness” because it is es-
sential for sustaining a functional stem cell population and 
establishing asymmetric division. β1 is also important to 
stem cell maintenance. CD133 is a marker because it is 
generally found in progenitor stem cells, linking it to a 
stem cell. CD133+ prostate cells use their stem cell like 
features developing prostatic-like acini in immunocom-
promised male mice. CD44 is a cell surface protein in-
volved in cell-to-cell interaction, migration and adhesion. 
Stem cell antigen 1 is expressed in the tissue of several 
stem and progenitor stem cells including, cardiac mam-
mary, hematopoietic, testicular, integumentary and mus-
cular. These markers have been found in prostate cancers 
thus giving credence to this theory (Tu & Lin, 2012). It was 
also found that cancers that had CD44 were much more 
tumorigenic and metastatic than cancers without CD44. 
This further proves that these markers have relevance 
when it comes to identifying cancers (Patrawala, et al., 
2007). These two studies indicate these classic stem cell 
markers are present in cancers and furthermore they 
enhance the growth and metastasis of the cancer when 
they’re present.
Breast cancer was also examined for these markers. 
The researchers analyzed surgically removed breast can-
cer tissue in 47 cases of only invasive duct carcinoma 
(IDC), 135 cases of IDC with ductal carcinoma in situ 
(DCIS), 35 cases of DCIS with microinvasion, 58 cases 
of pure DCIS and 73 cases of IDCs with adjacent DCIS. 
Four major subtypes of breast cancer were looked for in 
this analysis: luminal A, luminal B, HER2+, and basal-like. 
Each subtype was defined based on certain characters, 
luminal A (ER+ and/or PR+, HER2−), luminal B (ER+ and/
or PR+, HER2+), HER2+ (ER−, PR−, HER2+), basal-like 
(ER−, PR−, HER2−, basal cytokeratin+, and EGFR+/−). 
CD44+/CD24− and CD44−/CD24+ cells were found by 
way of double immunohistochemistry. It was found that 
luminal A tumors were least common in DCIS with mi-
croinvasion, luminal B tumors were least common in IDC 
alone, and basal-like tumors were least common in pure 
DCIS groups. CD44, CD24 and ALDH-1 markers were 
analyzed in normal breast tissue they were then com-
pared to cancerous breast tissue. In normal breast tissue 
CD44 was localized to the basal, myoepithelial, and a sub-
set of luminal epithelial cells. CD24 was found on the 
apical membranes of luminal cells while ALDH1 was het-
erogeneously expressed in luminal and basal cells. CD44 
was expressed in 57% of IDC only samples, 59% IDCs 
with DCIS samples, 62% of DCIS with microinvasion sam-
ples, and 85% of DCIS samples. CD24 was not nearly as 
prevalent as it was present in 24% IDC only tumors, 38% 
of IDC with DCIS tumors, 59% of DCIS with microin-
vasion tumors and 62% of DICS tumors. While ALDH1 
was not commonlyf ound in any of the four subtypes, it 
was far more common in IDC alone and IDC with DCIS 
than the other two subtypes of DCIS with microinvasion 
and DCIS alone, 9%, 6%, 3%, 3%, respectively (Park, et al., 
2010). These figures point to the fact that there is an as-
sociation between stem cell markers and breast cancer, 
further legitimizing the stem cell cancer theory.
Head and neck squamous cell carcinoma (HNSCC) 
such as cancers of the oral cavity, pharynx, larynx, pa-
ranasal sinuses, nasal cavity, salivary glands, or head and 
neck lymph nodes were studied to aid in further proving 
stem cell theory. Multi-modality therapy including surgery, 
has been emphasized as the method of treatment, yet 
the five-year survival rate for HNSCC is 0-40%, with no 
significant improvements in the past 30 years. A study 
was done using tissue specimens of cervical lymph nodes, 
primary tumors, and normal mucosa of patients under-
going surgical treatment of squamous cell carcinomas of 
multiple sites in the upper aerodigestive tract. A total of 
82 primary tumors and 24 metastatic lymph nodes from 
82 patients were analyzed. Several variants of CD44 were 
tested for: CD44s, CD44 v3, CD44 v6, and CD44 v10. It 
was found that a majority of the cells from both the prima-
ry tumors and lymph nodes presented strong expression 
of all 4 variants. CD44v3, v6 and v10 had a higher propor-
tion of being strongly expressed in lymph nodes than they 
did in primary tumors. Strong expression of CD44 v3 in 
primary tumors was also proven to have association with 
lymph node metastasis. Strong expression of CD44 v10 
in primary tumors showed association with radiation fail-
ure and with distant metastasis. The expression of CD44 
v6 was significantly associated with perineural invasion. 
Next, an analysis was performed with regard to disease 
free survival and overall survival. Overall tumor stage was 
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found to be correlated with shorter disease-free interval. 
Non-oropharyngeal primary site, positive cervical lymph 
nodes, distant metastasis, CD44 v6 and CD44 v10 ex-
pression, in primary tumors, were all significantly asso-
ciated with worse disease-free survival. Prior radiation 
therapy, expression of CD44s and, both the standard and 
variant form of CD44, in metastatic lymph nodes, were 
all not significantly associated with disease free interval 
or overall survival. Expression of CD44s, v3, v6, v10 were 
all associated with advanced primary tumor stage, treat-
ment failure, reduced disease-free interval, and metastasis 
(Wang, et al., 2009). These stem cell markers are all indic-
ative of very poor prognosis in HNCSS patients.
Researchers analyzed two cell groups of one patient 
who suffered from colon cancer, the primary tumor cell 
(SW480) and the metastatic lymph node (SW620). These 
cells were analyzed by phase contrast microscopy and 
were revealed as having two separate morphologies. 
SW480 was shown to have 80% of its fully adhered cells 
to be irregularly shaped, while 20% were spindle-like. 
SW620 displayed a more mixed morphology amongst 
its cells with 53% of its adhered cells as elongated spin-
dle-shaped and the remaining 47% were either more 
rounded spindles or irregularly shaped. The two cell lines 
displayed similar measures of cell growth normal to their 
respective cell line’s. When measuring migratory poten-
tial, SW480 cells were found to have a significantly higher 
migratory potential than SW620 cells. Several stem cell 
markers were analyzed in each cell line including, CD338, 
CD44, CD133, CD24 and CD49f. SW620 revealed a 
50.6% proportion of CD44+/CD133+ cells and SW480 
displayed 28.6%. But the proportion of CD44+/CD133- 
cells favored SW480 over SW620 with 54.3% and 20.7% 
respectively. CD44+/CD24- cells were abundant in both 
cell lines with SW480 having 62.7% and SW620 having 
75.3%. The presence of CD49f+/CD338- was the highest 
with SW480 and SW620 expressing it at 98 and 99%. 
Because of the prevalence in both groups of cell lines, 
it was deemed that these stem cell markers were not 
significant enough to differentiate between SW480 and 
SW620 in vitro cells (Slater, et al., 2018). While utilizing 
stem cells did not prove to be a method to differentiate 
between colon and metastatic tumors, it does prove the 
presence of these stem cell markers in cancers.
Utilizing the stem cell theory, researchers have devel-
oped a new treatment for leukemic stem cells (LSCs) 
that reside mainly in the bone marrow. Chronic myeloid 
leukemia (CML) and acute myeloid leukemia (AML) 
were analyzed. CML is categorized as a clonal hemato-
poietic stem cell that is caused by a translocation of a 
fusion of two parts of two separate chromosomes, ALB1 
(chromosome 9) and BCR (chromosome 22). AML is the 
most common form of adult leukemia and is categorized 
by infiltration of leukemic cells into the bone marrow 
and blood. The current therapies have an overall surviv-
al of roughly 40% in patients under 60 and decline by 
5-15% in older patients. AML is very difficult to treat be-
cause of how drug resistant the disease is. While CML 
and AML are both considered to have leukemia stem 
cells, the environment of the bone marrow that contains 
many growth factors only expedites the growth process. 
The markers used to indicate CML LSCs are CD25 IL-1 
and CD26 have been suggested as markers that are 
specific to this disease as opposed to other stem cells. 
CML LSCs vary from ALM LSC in that CML LSCs are 
defined as CD34+/CD38- fraction whereas AML LSCs 
are composed of heterogenous populations and aside 
from CD34+/CD38- they also are in CD34+/CD38+ and 
CD34-. The treatment method for these cancers is to 
disconnect the cancer from the growth promoting bone 
marrow environment thus making them more sensitive 
to conventional therapy. There are several compounds 
being studied as possible ways to disconnect the AML or 
CML from the bone marrow such as: BL-8040, CAR-LMC, 
Ruxolitinib, AMD3100, TH-302, Aflibercept, AS101, AMG 
386, SRF231, TTI-621, CC90002 Hu5F9-G4, LY3039478. 
These compounds all have different target cites but are 
all designed to disconnect the cancer from the growth 
advances provided by the bone marrow. IL-1RAP has also 
been shown as a good marker to target CML LSCs in a 
more selective manor because of its specific expression 
in CML LSCs. Inducing apoptosis is a common approach 
to AML treatment (Houshmand, et al., 2019).
Antibodies targeting IL-1RAP were thought as a pos-
sible way to treat CML LSCs without harming normal 
stem cells. The antibodies mAb81.2 and mAb3F8 were 
used and generated by the hybridoma technique. The cell 
cultures were bone marrow and peripheral blood from 
healthy volunteers and CML patients. The CML cells were 
stimulated with IL-1B, IL-33, IL-36 or SCF. IL-1B and SCF 
resulted in a slight expansion of CD34- CML progeni-
tor cells. The stimulation as a result IL-1B on CD34+/
CD38- cells resulted in a 30-fold increase in cell numbers 
as opposed to normal cells that responded weakly. In vivo 
samples were studied to show the therapeutic effects of 
IL-1RAP antibodies. Mice who expressed IL-1RAP were 
treated with mAb81.2 which resulted in prolonged sur-
vival. The treatment proved to be very effective to the 
point where the treatment was stopped after 45 days, yet 
the mice survived an additional 12 days with 2 mice living 
until day 101. Several of these mice displayed significantly 
lower bone marrow leukemic cell levels compared with 
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control mice. These antibodies are effective because they 
block the signals of IL-1 as well as initiating effector cells 
to kill tumor cells. This treatment does not affect normal 
human stem cells because normal stem cells do not ex-
press IL1RAP (Agerstam, et al., 2016). This study shows 
tremendous promise of utilizing the stem cell theory’s 
principles as a route of treatment.
Conclusion
While there is a lot of data supporting each understand-
ing of cancer development, there seems to be one correct 
approach to cancer; it appears that the correct answer is 
not one of these three theories rather a combination 
of the immunological theory and the somatic mutation 
theory. The immunological theory seems almost entirely 
correct based on the utilization of CAR-T and CAR-NK, 
DC-CIK as successful methods of treatment as well as the 
case-report of a tetanus shot proving to increase cancer 
prognosis. The issue with solely using the immunological 
theory is that it better explains the treatment of cancer 
and what should happen to prevent cancers from devel-
oping (NK cells) but it does not address why a cancer 
cell forms. Rather it only states once a cancer forms the 
immune system should prevent it from developing. The 
somatic mutation theory explains why a cancer starts 
to develop but the immunological theory explains how 
to prevent it from continual growth. These theories, in 
tandem, are the best explanation of cancer development.
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